IP Library Granted Patent US 10,525,003
Granted Patent B2
US 10,525,003 · App. 11/992,823 · Granted Jan 7, 2020

Antifungal composition

Inventor: Friedrich Karl Mayer (Oberwil, CH)
Assignee: GSK CONSUMER HEALTHCARE S.A.
A61K9/0014A61K9/06A61K9/7015A61K31/137A61K31/5375A61K47/32A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,525,003
App. No.
11/992,823
Granted
Jan 7, 2020
Kind
B2
Abstract

The invention provides a topical liquid antifungal composition containing an antifungal agent, a film-forming agent and a solvent. The composition is applied on the infected skin area to form a film that delivers the active agent. The invention also provides a method for treating a fungal infection on the skin by applying the topical antifungal composition that forms a film on the skin.

Claims (32)

1. A one dose method of treatment of a dermatophyte skin infection selected from tinea pedis, tinea corporis, tinea cruris and tinea capitis, said method comprising topically applying to the infected skin a single dose of a film-forming composition capable of adhering to the skin for a period of at least 48 hours, and maintaining said composition on the skin for at least 48 hours, said composition comprising upon application

a) an antifungal agent terbinafine or a salt thereof,

b) a hydrophilic film-forming agent comprising a hydroxyalkyl cellulose, and

c) a hydrophobic film-forming polymer selected from the group consisting of octylacrylamide, octylacylamide acrylate copolymer; octylpropenamide acrylate copolymer, in a solvent selected from an aqueous solvent, organic solvent, or a mixture thereof,

whereby said single dose application of said composition results in sufficient absorption of the antifungal agent by the stratum corneum to provide effective treatment of the dermatophyte skin infection, said effective treatment consisting of a mycological cure rate of at least 50% at six weeks following application of said single dose.

2. The method of claim 1 wherein said hydrophobic film-forming polymer is octylacrylamide acrylate copolymer.

3. The method of claim 1 wherein said composition comprises between 0.75% w/w and 20% w/w of terbinafine or a salt thereof, 0.05% w/w and 30% w/w of a mixture of octylacrylamide acrylate copolymer and hydroxypropylcellulose, and a solvent selected from the group consisting of ethanol, isopropanol, acetone and ethyl acetate.

4. The method of claim 1 wherein said hydrophobic film-forming polymer is octylacrylamide acrylate copolymer present in an amount of about 3 to about 7% w/w.

5. The method of claim 1 wherein said composition comprises between 0.75% w/w and 20% w/w of terbinafine or a salt thereof, between 0.05% w/w and 30% w/w of a mixture of octylacrylamide acrylate copolymer and hydroxypropylcellulose, and a solvent selected from the group consisting of ethanol and a mixture of ethanol and water.

6. The method of claim 5 wherein the solvent is a mixture of ethanol and water and the ratio of water to solvent is below 1:3.

7. The method of claim 1 wherein the plasticizer comprises a medium chain triglyceride.

8. The method of claim 1 comprising 1% terbinafine or salt thereof.

9. The method of claim 1 wherein the hydrophilic film-forming agent is hydroxypropylcellulose.

10. The method of claim 3 wherein the solvent further comprises water.

11. A method of treating skin infected with dermatophytes in a human in need thereof, the method comprising topically applying to the infected skin a one-time dose of a film-forming composition capable of adhering to the skin for a period of at least 48 hours, maintaining said composition on the skin for at least 48 hours, said composition comprising upon application

a) an antifungal agent terbinafine or a salt thereof,

b) a hydrophilic film-forming agent comprising a hydroxyalkyl cellulose, and

c) a hydrophobic film-forming polymer selected from the group consisting of octylacrylamide, octylacylamide acrylate copolymer; octylpropenamide acrylate copolymer, in a solvent selected from an aqueous solvent, organic solvent, or a mixture thereof,

whereby said single dose application of said composition provides an effective treatment of the dermatophyte skin infection, said effective treatment consisting of a mycological cure rate of at least 50% at six weeks following application of said single dose wherein the composition additionally comprises a plasticizer selected from the group consisting of dialkylphthalates, hydroxyl-fatty acid oils, triglycerides and silicon oils.

12. The method according to claim 11 wherein the terbinafine or a salt thereof, is present in an amount of about 1 to about 10% w/w.

13. The method according to claim 12 comprising 10% terbinafine or salt thereof.

14. The method according to claim 12 comprising 5% terbinafine or salt thereof.

15. The method according to claim 12 comprising 1% terbinafine or salt thereof.

16. The method according to claim 11 wherein the hydrophilic film-forming agent is present in an amount of about 1 to about 10% w/w.

17. The method according to claim 11 wherein the hydrophobic polymer is present in an amount of about 1 to about 7% w/w.

18. The method according to claim 11 wherein the solvent is selected from ethanol isopropanol, acetone and ethyl acetate.

19. The method according to claim 18 wherein the solvent is a mixture of water and a solvent.

20. The method according to claim 19 wherein the water to solvent is in a ratio of below 1:3.

21. The method according to claim 19 wherein the solvent is ethanol.

22. The method according to claim 20 wherein the solvent is ethanol.

23. The method according to claim 11 wherein the plasticizer is a medium chain triglyceride.

24. The method according to claim 11 wherein the dermatophyte skin infection is tinea pedis, tinea corporis, tinea crusis or tinea captitis.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2024
From: HALEON CH SARL
To: KARO HEALTHCARE AB
Reel/Frame 069582/0835 →
CHANGE OF NAME Recorded Mar 1, 2024
From: GSK CONSUMER HEALTHCARE SARL
To: HALEON CH SARL
Reel/Frame 066618/0404 →
CHANGE OF LEGAL ENTITY Recorded Apr 12, 2022
From: GSK CONSUMER HEALTHCARE S.A.
To: GSK CONSUMER HEALTHCARE SARL
Reel/Frame 059678/0841 →
CHANGE OF NAME Recorded Nov 12, 2019
From: NOVARTIS CONSUMER HEALTH S.A.
To: GSK CONSUMER HEALTHCARE S.A.
Reel/Frame 050989/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2017
From: NOVARTIS AG
To: NOVARTIS CONSUMER HEALTH SA
Reel/Frame 041378/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2008
From: MAYER, FRIEDRICH KARL
To: NOVARTIS AG
Reel/Frame 020779/0966 →
Continuity (3)
Provisional Application 60723163 · Oct 3, 2005
Provisional Application 60722625 · Sep 29, 2005
Related Publication 20090088434A1 · Apr 2, 2009